Edition:
United Kingdom

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

104.74USD
23 Feb 2018
Change (% chg)

$0.44 (+0.42%)
Prev Close
$104.30
Open
$104.60
Day's High
$104.75
Day's Low
$104.55
Volume
656,760
Avg. Vol
555,282
52-wk High
$104.75
52-wk Low
$48.14

Latest Key Developments (Source: Significant Developments)

Bioverativ Q4 Revenue Rose 28.3 Percent To $328.7 Million
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Bioverativ Inc ::BIOVERATIV REPORTS FOURTH QUARTER AND FULL YEAR 2017 PERFORMANCE.Q4 REVENUE ROSE 28.3 PERCENT TO $328.7 MILLION.QTRLY ‍SHR $1.30​.  Full Article

Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Bioverativ Inc ::BIOVERATIV SAYS REGARDING TERMINATION OF MERGER DEAL WITH SANOFI UNDER CERTAIN CIRCUMSTANCES CO WILL BE REQUIRED TO PAY FEE OF $326 MILLION - SEC FILING.  Full Article

Sanofi nears deal to buy Hemophilia drugmaker Bioverativ for over $11.5 bln - WSJ
Monday, 22 Jan 2018 

Jan 21 (Reuters) - :SANOFI NEARS DEAL TO BUY HEMOPHILIA DRUGMAKER BIOVERATIV FOR MORE THAN $11.5 BILLION - WSJ, CITING SOURCES‍​.  Full Article

Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patients
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Bioverativ Inc ::BIOVERATIV’S INVESTIGATIONAL BIVV009 DEMONSTRATES SAFETY, TOLERABILITY AND EFFICACY IN PHASE 1B CLINICAL TRIAL IN COLD AGGLUTININ DISEASE (CAGD) PATIENTS.BIOVERATIV INC - PHASE 1B RESULTS ACHIEVE PRIMARY AND SECONDARY ENDPOINTS IN CAGD COHORT.BIOVERATIV - FOUND STATISTICALLY SIGNIFICANT OVERALL INCREASED RATE OF THROMBOEMBOLIC EVENTS IN CAGD PATIENTS VERSUS MATCHED CONTROLS.  Full Article

Bioverativ says U.S. ‍FDA Has Approved Updated Labeling For Alprolix ​
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Bioverativ Inc ::BIOVERATIV INC - U.S. ‍FDA HAS APPROVED UPDATED LABELING FOR ALPROLIX ​.BIOVERATIV INC SAYS LABEL UPDATE INCLUDES ADDITION OF PEDIATRIC DATA RELATED TO PROPHYLACTIC TREATMENT WITH ALPROLIX.  Full Article

Bioverativ reports Q3 earnings per share $0.63
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Bioverativ Inc :Bioverativ reports third quarter 2017 performance.Q3 non-gaap earnings per share $0.80.Q3 gaap earnings per share $0.63.Q3 revenue $291.6 million versus i/b/e/s view $285.5 million.Q3 earnings per share view $0.69 -- Thomson Reuters I/B/E/S.  Full Article

Valueact Capital Management LLC reports 3.8 pct stake in Bioverativ Inc as of July 13 - SEC filing
Monday, 17 Jul 2017 

July 17 (Reuters) - Bioverativ Inc :Valueact Capital Management LLC reports 3.8 percent stake in Bioverativ Inc as of July 13 versus 7.5 percent stake as of Feb 28 - SEC filing.  Full Article

Primecap Management Company reports 7.19 pct passive stake in Bioverativ - SEC filing
Monday, 6 Mar 2017 

Bioverativ Inc:Primecap management company reports a 7.19 percent passive stake in bioverativ inc as of feb 28, 2017- SEC filing.  Full Article

UPDATE 1-‍Sobi Q4 tops forecast but 2018 outlook below market expectations​

Feb 22 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Thursday a bigger fourth-quarter profit jump than expected but guided for slightly slower profit growth in 2018 than estimated by analysts.